Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Apr;12(6):991-4.
doi: 10.1517/14656566.2011.565332.

Treatment for relapsed Hodgkin lymphoma: refinement of chemotherapy or targeted treatment?

Sheila A Doggrell  1
Affiliations
Comment

Treatment for relapsed Hodgkin lymphoma: refinement of chemotherapy or targeted treatment?

Sheila A Doggrell. Expert Opin Pharmacother. 2011 Apr.

Abstract

The prognosis for those with relapsed Hodgkin lymphoma is poor. This evaluation is of two new approaches to the treatment of relapsed Hodgkin lymphoma. First, is a refinement of the chemotherapy for the relapsed condition, which showed that adding SHDCT (sequential high-dose chemotherapy of cyclophosphamine, uromitexane, granulocyte colony-stimulating factor, methotrexate, vincristine, etoposide) did not improve outcome. Second, is new targeted treatment for relapsed Hodgkin disease--brentuximab vedotin, which has an antitubulin agent (monomethylauristatin E) attached to a CD30-specific antibody. This agent gave promising results in a Phase I clinical trial in subjects with relapsed Hodgkin lymphoma. Brentuximab vedotin has produced good initial findings in the treatment of Hodgkin lymphoma and needs to be tested more widely.

PubMed Disclaimer

Comment on

  • Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.
    Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A. Josting A, et al. J Clin Oncol. 2010 Dec 1;28(34):5074-80. doi: 10.1200/JCO.2010.30.5771. Epub 2010 Oct 25. J Clin Oncol. 2010. PMID: 20975066 Clinical Trial.
  • Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Younes A, et al. N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965. N Engl J Med. 2010. PMID: 21047225 Clinical Trial.

LinkOut - more resources